Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.2% – What’s Next?

Eli Lilly and Company (NYSE:LLY) was down 2.2% on Tuesday . The stock traded as low as $1,113.55 and last traded at $1,123.60. Approximately 2,272,672 shares changed hands during mid-day trading, a decline of 26% from the average daily volume of 3,060,302 shares. The stock had previously closed at $1,149.36.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s Mounjaro received FDA approval to reduce heart-attack and stroke risk in certain adults with type 2 diabetes. The expanded indication could increase prescribing, strengthen Mounjaro’s competitive position and extend growth beyond blood-sugar control. Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
• Positive Sentiment: Analyst coverage remains broadly favorable, with Wall Street’s average recommendation continuing to signal optimism toward LLY’s growth outlook. Wall Street Bulls Look Optimistic About Lilly
• Positive Sentiment: Lilly is expanding its neuroscience pipeline through internal development and acquisitions, potentially creating a longer-term growth engine alongside its diabetes and obesity portfolio. Analysts also see substantial opportunity in the company’s incretin drugs, including Zepbound and Mounjaro. Lilly Builds Neuroscience into a New Long-Term Growth Driver
• Neutral Sentiment: Recent acquisitions could diversify Lilly and support future growth, but investors must weigh the deals against integration costs, competition and time-limited patent protection for its leading GLP-1 medicines. Eli Lilly Has Been on an Acquisition Spree
• Negative Sentiment: Novartis’ failure in a closely watched cardiovascular trial damaged sentiment toward the broader Lp(a) cholesterol-drug class. Although Lilly was not the direct trial sponsor, investors appear concerned about cardiovascular pipeline risk and the broader healthcare sector sell-off. Eli Lilly Stock Falls on Competitor Novartis’ Cholesterol Drug Setback
• Negative Sentiment: Technical analysts cited a breakdown in key support levels, adding short-term pressure to LLY even as its long-term fundamentals remain strong. Why Is Eli Lilly Stock Falling Tuesday?

Analyst Ratings Changes

Several brokerages recently commented on LLY. Wolfe Research reissued an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research note on Friday, August 7th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Finally, Guggenheim increased their price target on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company Stock Down 2.2%

The stock’s fifty day simple moving average is $1,190.13 and its 200-day simple moving average is $1,070.66. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market cap of $1.06 trillion, a P/E ratio of 37.70, a P/E/G ratio of 1.42 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter last year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 23.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Nykredit A S bought a new stake in Eli Lilly and Company during the second quarter worth $392,919,000. Parkside Financial Bank & Trust raised its stake in Eli Lilly and Company by 4.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 8,108 shares of the company’s stock valued at $9,725,000 after acquiring an additional 359 shares during the period. MLG Wealth Management DBA Pine Grove Financial Group lifted its holdings in Eli Lilly and Company by 10.4% during the second quarter. MLG Wealth Management DBA Pine Grove Financial Group now owns 677 shares of the company’s stock valued at $810,000 after purchasing an additional 64 shares during the last quarter. Range Advisory LLC boosted its position in Eli Lilly and Company by 71.0% during the second quarter. Range Advisory LLC now owns 2,597 shares of the company’s stock worth $3,115,000 after purchasing an additional 1,078 shares during the period. Finally, Parrish Capital LLC bought a new position in Eli Lilly and Company during the second quarter worth about $205,000. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.